title: Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery.
abstract: The reversibility of neuropathic lysosomal storage diseases, including MPS IIIA, is a major goal in therapeutic development, due to typically late diagnoses and a large population of untreated patients. We used self-complementary adeno-associated virus (scAAV) serotype 9 vector expressing human N-sulfoglucosamine sulfohydrolase (SGSH) to test the efficacy of treatment at later stages of the disease. We treated MPS IIIA mice at 1, 2, 3, 6, and 9 months of age with an intravenous injection of scAAV9-U1a-hSGSH vector, leading to restoration of SGSH activity and reduction of glycosaminoglycans (GAG) throughout the central nervous system (CNS) and somatic tissues at a dose of 5E12 vg/kg. Treatment up to 3 months age improved learning ability in the Morris water maze at 7.5 months, and lifespan was normalized. In mice treated at 6 months age, behavioral performance was impaired at 7.5 months, but did not decline further when retested at 12 months, and lifespan was increased, but not normalized. Treatment at 9 months did not increase life-span, though the GAG storage pathology in the CNS was improved. The study suggests that there is potential for gene therapy intervention in MPS IIIA at intermediate stages of the disease, and extends the clinical relevance of our systemic scAAV9-hSGSH gene delivery approach.
authors.affiliation: Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio, USA.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Fu
authors.affiliation: Department of Biological Sciences, University of North Carolina , Charlotte, North Carolina, USA.
authors.forename: Marcela P
authors.initials: MP
authors.lastname: Cataldi
authors.affiliation: Biomedical Sciences Graduate Program, The Ohio State University , Columbus, Ohio, USA.
authors.forename: Tierra A
authors.initials: TA
authors.lastname: Ware
authors.affiliation: Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio, USA.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Zaraspe
authors.affiliation: Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio, USA.
authors.forename: Aaron S
authors.initials: AS
authors.lastname: Meadows
authors.affiliation: Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio, USA.
authors.forename: Darren A
authors.initials: DA
authors.lastname: Murrey
authors.affiliation: Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA; Department of pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
authors.forename: Douglas M
authors.initials: DM
authors.lastname: McCarty